Schnieders Capital Management LLC Reduces Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Schnieders Capital Management LLC lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 8.2% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 6,700 shares of the biopharmaceutical company’s stock after selling 600 shares during the period. Schnieders Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $319,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc lifted its position in shares of Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after purchasing an additional 1,229,553 shares during the last quarter. BlackRock Inc. lifted its position in shares of Bristol-Myers Squibb by 0.9% during the fourth quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after purchasing an additional 999,193 shares during the last quarter. Northern Trust Corp lifted its position in shares of Bristol-Myers Squibb by 4.4% during the fourth quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after purchasing an additional 954,877 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Bristol-Myers Squibb by 1.1% during the fourth quarter. Bank of New York Mellon Corp now owns 17,303,884 shares of the biopharmaceutical company’s stock worth $899,456,000 after purchasing an additional 180,711 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $797,038,000. Institutional investors and hedge funds own 77.53% of the company’s stock.

In other news, Director Theodore R. Samuels II bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was purchased at an average price of $47.29 per share, with a total value of $236,450.00. Following the completion of the acquisition, the director now directly owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Karen Murphy Santiago sold 3,065 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the sale, the insider now directly owns 3,066 shares of the company’s stock, valued at approximately $145,818.96. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.

Several research firms have recently weighed in on BMY. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research report on Tuesday, May 7th. Goldman Sachs Group initiated coverage on Bristol-Myers Squibb in a research note on Tuesday, May 28th. They set a “buy” rating and a $54.00 price target on the stock. BMO Capital Markets raised their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target on the stock. in a research note on Monday, May 20th. Finally, ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $56.34.

Shares of BMY stock traded up $0.85 during trading hours on Monday, reaching $46.20. 14,049,600 shares of the company’s stock were exchanged, compared to its average volume of 17,464,496. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $63.69. The stock has a market cap of $74.18 billion, a PE ratio of 11.61, a PEG ratio of 2.11 and a beta of 0.71. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.79 and a current ratio of 1.93. The firm has a fifty day moving average price of $46.77.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.01. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The business had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the previous year, the firm earned $0.94 earnings per share. The company’s revenue was up 14.0% on a year-over-year basis. On average, equities analysts expect that Bristol-Myers Squibb Co will post 4.2 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date is Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: What can cause a stock to outperform?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.